非营利药物开发模式是抗菌药物耐药性解决方案的一部分
本文为一篇观点类文章,讨论抗菌药物耐药性(AMR)背景下新抗生素研发的资金与可及性问题。文章指出推动资金已重振临床前AMR管线,但新抗生素收入不足以吸引商业开发者;作者主张以公共卫生需求为驱动,由公共资金资助的非营利研发组织主导开发,以实现全球公平可及。
要点
- 推动资金重振了临床前AMR管线,但新抗生素盈利不足仍是核心障碍。
- 公共卫生需求应成为抗生素开发的首要驱动因素,需改善资助方的优先级排序与政府监督。
- 非营利研发组织不受商业盈利要求约束,可与公私各方合作提供新抗生素。
核心结论
- 公共卫生需求应作为抗生素开发的首要驱动,非营利研发组织在公共资助方支持下可可行地提供新抗生素并保障全球公平可及。
研究设计与样本
- 本文为观点类文章,未报告系统检索范围或样本量。
主要发现
- 推动资金已重振临床前AMR管线,CARB-X、BARDA及AMR行动基金的投入将帮助数种新抗生素获得监管批准。
- 商业开发者认为新抗生素产生的收入不足以盈利,难以满足未满足需求。
- 改善资助方的优先级排序与政府监督是必要的第一步。
临床怎么用
- 在抗生素研发与可及性决策中,可将公共卫生需求置于商业回报之上,并考虑由公共资金支持的非营利研发模式作为补充路径。
局限性
- 本文为观点性论述,未提供原始研究数据或定量证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibiotics underpin modern medicine and are critical for pandemic preparedness. Push funding has revitalized the preclinical antimicrobial resistance (AMR) pipeline and government funding via CARB-X and BARDA, as well as private sector-led investment via the AMR Action Fund, will help several new antibiotics obtain regulatory approval. Nevertheless, revenues generated by new antibiotics are not considered sufficiently profitable by commercial developers to address unmet need. The question remains: Who could viably fund development and secure global equitable access for new antibiotics? Public health need should be the primary driver for antibiotic development. Improved prioritization and government oversight by funders who allocate public resources are a needed first step. In this framework, nonprofit research and development organizations, with support from public funders, and unconstrained by commercial profitability requirements are well positioned to work with public and private actors to viably provide new antibiotics to all in need.
引用
- Piddock LJV, Paccaud JP, O'Brien S, et al. A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution. Clin Infect Dis. 2022. PMID: 34618892. doi:10.1093/cid/ciab887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。